Philip Hykin

Moorfields Eye Hospital NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

39h-index5.9kcitations162works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Retinal Diseases and Treatments(121), Retinal Imaging and Analysis(84), Retinal and Optic Conditions(70), Glaucoma and retinal disorders(31), Ocular Diseases and Behçet’s Syndrome(21)

Publications162 total

Outcomes of anti-VEGF treatment for macular edema secondary to central retinal vein occlusion in patients with poor baseline visual acuity
Canadian Journal of Ophthalmology·2023· 1 cited
RETINAL NONPERFUSION IN THE EARLY TREATMENT DIABETIC RETINOPATHY STUDY SEVEN FIELDS COMPARED WITH WIDEFIELD FLUORESCEIN ANGIOGRAPHY
Retina·2022· 1 cited
Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti–Vascular Endothelial Growth Factor Therapy
JAMA Ophthalmology·2022· 18 citedOpen Access
Neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E): post-hoc analysis of injection intensive (I-I) requirement for patients in the ARIES study
Investigative Ophthalmology & Visual Science·2021· 1 citedOpen Access
Association between visual acuity and intraretinal (IRF) or subretinal (SRF) fluid in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E): a post-hoc analysis of the ARIES study
Investigative Ophthalmology & Visual Science·2021Open Access
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
PharmacoEconomics·2021Open Access
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT
Health Technology Assessment·2021· 17 citedOpen Access
The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy
Eye·2021· 13 citedOpen Access
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
PharmacoEconomics·2021· 11 citedOpen Access
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina·2021· 87 citedOpen Access
Predictors of Visual Acuity Outcomes after Anti–Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion
Ophthalmology Retina·2021· 35 citedOpen Access
Long-term follow-up of a case of posterior microphthalmos (PRSS56) with hyperautofluorescent retinal pigment epithelial deposits
European Journal of Ophthalmology·2020· 4 cited
Comparison of treat-and-extend (T&E) dosing regimens and visual outcomes in the ARIES and ALTAIR studies of intravitreal aflibercept (IVT-AFL) in neovascular age-related macular degeneration (nAMD)
Investigative Ophthalmology & Visual Science·2020· 4 citedOpen Access
Efficacy of Intravitreal Aflibercept Treat-and-Extend Regimen Over 2 Years for Neovascular Age-Related Macular Degeneration: ARIES Study
Investigative Ophthalmology & Visual Science·2020· 3 citedOpen Access
Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial
Value in Health·2020· 16 citedOpen Access
One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab
European Journal of Ophthalmology·2020· 7 cited
Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes
European Journal of Ophthalmology·2020· 28 cited
PSS25 MAPPING FROM VISUAL ACUITY TO UTILITY IN PATIENTS WITH MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION USING DATA FROM THE LEAVO TRIAL
Value in Health·2019
Confirmation That Angioid Streaks Are Not Common in Ehlers-Danlos Syndrome
JAMA Ophthalmology·2019· 9 cited
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion
JAMA Ophthalmology·2019· 108 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Sobha Sivaprasad(20), Jayashree Ramu(8), Robin Hamilton(7), Tünde Pető(7), James Bainbridge(7), Luke Nicholson(7), Namritha Patrao(6), Praveen J. Patel(6), Frank G. Holz(5), Giovanni Staurenghi(5), Catherine Egan(5), A Toby Prevost(5), Joana C. Vasconcelos(5), Ranjan Rajendram(4), Catey Bunce(4), Caroline Murphy(4), Joanna Kelly(4), Usha Chakravarthy(4), Ramin Tadayoni(3), Stephen Beatty(3)